Search Results

Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in November 2021.

Alora Pharmaceuticals today announced its subsidiaries Avion Pharmaceuticals, LLC and Acella Pharmaceuticals, LLC earned the top spot for small companies in MedReps Best Places to Work in Medical Sales 2022 survey, marking the fourth consecutive year of being honored.

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced the addition of Divigel® (estradiol gel) 0.1%–the #1 prescribed transdermal estrogen gel*–to the company’s growing women’s health portfolio.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, has announced a license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated, both wholly owned subsidiaries of Aspen Pharmacare Holdings Limited, for the exclusive rights to relaunch Cenestin ® (synthetic conjugated estrogen

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, and affiliate company Acella Pharmaceuticals, LLC, have earned back-to-back annual recognition as the “Best Place to Work in Medical Sales: Small Pharma Category.” This announcement was made by MedReps, the leading job site for experienced industry professionals. In a

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, announced its gout prophylaxis product, GLOPERBA® (colchicine), is now commercially available in pharmacies across the United States.

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, announces it received the 2020 “Best Place to Work in Medical Sales: Small Pharma Category” award from MedReps, the leading job site for experienced industry professionals, including those seeking positions in medical and pharmaceutical sales.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.